
Evolus (EOLS) Stock Forecast & Price Target
Evolus (EOLS) Analyst Ratings
Bulls say
Evolus Inc. reported a 3.7% year-over-year increase in total net revenue, reaching $69.4 million, primarily due to higher volumes of Jeuveau and a successful launch of the Evolysse dermal filler line. The company anticipates Evolysse will contribute approximately 10-12% to its 2025 top-line guidance, reflecting positive initial demand from younger consumers who are increasingly favoring aesthetic treatments. Additionally, the management's confidence in Jeuveau's potential to gain market share, supported by its superior effectiveness, along with the promising growth trajectory in the cash-pay aesthetic market, bolsters the overall outlook for Evolus.
Bears say
Evolus has experienced a decline in adjusted gross margin, dropping from 71.5% to 66.5%, primarily due to a higher proportion of international sales and introductory pricing aimed at increasing product adoption. The company has also revised its 2025 net revenue guidance downward to $295-$305 million, reflecting a significant reduction in expected growth from a previous forecast of 30%-33% to just 11%-15%. Additionally, the overall market for aesthetic procedures has been under pressure, evidenced by a reported decline in procedure volumes and a 13% quarter-over-quarter drop in Jeuveau sales, marking the first year-over-year decline since its inception in 2019.
This aggregate rating is based on analysts' research of Evolus and is not a guaranteed prediction by Public.com or investment advice.
Evolus (EOLS) Analyst Forecast & Price Prediction
Start investing in Evolus (EOLS)
Order type
Buy in
Order amount
Est. shares
0 shares